BioCentury | Dec 8, 2017
Translation in Brief

Multi-use p53 sensor

...extended to sense other tumor suppressors or oncogenes. Aprea Therapeutics AB, City of Hope and MultiVir Inc....
...p53 deficient cells.” Nature Communications (2017) Michael Leviten, Senior Writer Aprea Therapeutics AB City of Hope Dresden University of Technology MultiVir Inc. Tumor...
BioCentury | Nov 2, 2017
Targets & Mechanisms

Golden State of DUBs

...Therapeutics AB has the chaperone-like compound APR-246 in Phase II testing for ovarian cancer, and MultiVir Inc....
...MRC), London, U.K. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Mission Therapeutics Ltd., Cambridge, U.K. MultiVir Inc....
BioCentury | Dec 15, 2016
Product R&D

p53 and Ras: Back from the dead

...Online Intelligence; company websites Target Modality Companies/Institutions Technology description Phase of development p53 Gene therapy MultiVir Inc....
...venture rounds for a Scandinavian biotech. Other strategies involve using gene therapy to restore p53. MultiVir...
...Calif. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Kyras Therapeutics Inc., New York, N.Y. MultiVir Inc....
BioCentury | Jul 23, 2015
Tools & Techniques

Gene therapy's coming of age

...Ltd. , Etubics Corp. , GenVec Inc. , Milo Biotechnology LLC , Momotaro-Gene Inc. , MultiVir Inc....
BioCentury | Jun 8, 2015
Financial News

MultiVir withdraws IPO

...Date announced: 2015-05-27 Type: IPO Underwriters: RBC Capital Markets; Nomura; Cantor Fitzgerald; LifeSci Capital Note: MultiVir...
BioCentury | Apr 27, 2015
Financial News

MultiVir amends IPO

...million Price: $12-$14 Underwriters: RBC Capital Markets; Nomura; Cantor Fitzgerald; LifeSci Capital Overallotment: 690,000 Note: MultiVir...
BioCentury | Apr 6, 2015
Financial News

MultiVir proposes IPO

...to $70 million Shares: TBD Price: TBD Underwriters: RBC Capital Markets; Nomura; Cantor Fitzgerald Note: MultiVir...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

...3/31/15 Up to $57.5M Ph II CoLucid Pharmaceuticals Inc. 3/30/15 Up to $86.3M Ph III MultiVir Inc....
Items per page:
1 - 8 of 8
BioCentury | Dec 8, 2017
Translation in Brief

Multi-use p53 sensor

...extended to sense other tumor suppressors or oncogenes. Aprea Therapeutics AB, City of Hope and MultiVir Inc....
...p53 deficient cells.” Nature Communications (2017) Michael Leviten, Senior Writer Aprea Therapeutics AB City of Hope Dresden University of Technology MultiVir Inc. Tumor...
BioCentury | Nov 2, 2017
Targets & Mechanisms

Golden State of DUBs

...Therapeutics AB has the chaperone-like compound APR-246 in Phase II testing for ovarian cancer, and MultiVir Inc....
...MRC), London, U.K. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Mission Therapeutics Ltd., Cambridge, U.K. MultiVir Inc....
BioCentury | Dec 15, 2016
Product R&D

p53 and Ras: Back from the dead

...Online Intelligence; company websites Target Modality Companies/Institutions Technology description Phase of development p53 Gene therapy MultiVir Inc....
...venture rounds for a Scandinavian biotech. Other strategies involve using gene therapy to restore p53. MultiVir...
...Calif. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Kyras Therapeutics Inc., New York, N.Y. MultiVir Inc....
BioCentury | Jul 23, 2015
Tools & Techniques

Gene therapy's coming of age

...Ltd. , Etubics Corp. , GenVec Inc. , Milo Biotechnology LLC , Momotaro-Gene Inc. , MultiVir Inc....
BioCentury | Jun 8, 2015
Financial News

MultiVir withdraws IPO

...Date announced: 2015-05-27 Type: IPO Underwriters: RBC Capital Markets; Nomura; Cantor Fitzgerald; LifeSci Capital Note: MultiVir...
BioCentury | Apr 27, 2015
Financial News

MultiVir amends IPO

...million Price: $12-$14 Underwriters: RBC Capital Markets; Nomura; Cantor Fitzgerald; LifeSci Capital Overallotment: 690,000 Note: MultiVir...
BioCentury | Apr 6, 2015
Financial News

MultiVir proposes IPO

...to $70 million Shares: TBD Price: TBD Underwriters: RBC Capital Markets; Nomura; Cantor Fitzgerald Note: MultiVir...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

...3/31/15 Up to $57.5M Ph II CoLucid Pharmaceuticals Inc. 3/30/15 Up to $86.3M Ph III MultiVir Inc....
Items per page:
1 - 8 of 8